AI-generated from publicly available materials.Silo Pharma has finalized an asset purchase agreement with Parkview Consulting, acquiring software and intellectual property in exchange for 165,000 shares of common stock.
The agreement allows Silo Pharma to enhance its technological capabilities by obtaining specific software, technology, domain names, and associated intellectual property. The transaction will see the issuance of shares subject to a lock-up period of up to 12 months, which can be lifted under certain conditions, such as a change in control or company consent. This strategic move is part of Silo Pharma's ongoing efforts to bolster its technological infrastructure.
Key aspects of the agreement include the customary representations, covenants, and indemnities typical for such transactions. The deal was signed on August 18, 2026, and is effective immediately, with no fixed termination date, allowing for flexibility in the partnership.
This acquisition highlights Silo Pharma's proactive approach to expanding its tech capabilities, which may position the company for enhanced competitiveness in the life sciences sector. By integrating new software and IP, Silo Pharma could potentially accelerate its development processes and improve operational efficiency, ultimately benefiting its strategic objectives.